Compare Arm Holdings plc (ARM) vs Oscar Health Inc (OSCR) Price & Performance

ARM stock trades at $282.57, down 1.43% over 24 hours, with a bullish technical outlook supported by moving averages and key support at $272. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 beating the $0.40 estimate. Revenue grew to $4.01B in 2025, with a net income margin of 20.25%, though valuation multiples remain elevated with a P/E of 273.32.

The outlook is positive due to AI-driven growth in licensing and royalties, with management targeting $25B revenue by FY31. However, risks include stretched valuation, smartphone market headwinds, and execution challenges. Analyst consensus is bullish with a $329.80 price target, suggesting 17% upside from current levels.

OSCR trades at $27.90, up 5.12% with strong recent earnings performance including Q2 2026 EPS beating estimates. The stock shows bearish technical signals but positive fundamental momentum with revenue growth from $11.7B to $15.3B and a swing to profitability. Recent news highlights record 2026 profitability and raised full-year guidance.

The outlook appears constructive with analyst consensus target of $32.50 offering 16% upside. Key risks include execution on growth targets and competitive pressures. The valuation remains attractive with P/S of 0.53, though investors should monitor Q3 earnings delivery against expectations.